Cancer of the Ovary
9
1
1
3
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
44.4%
4 terminated out of 9 trials
42.9%
-43.6% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Blood Collection From People With Ovarian Cancer
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer